Channel Therapeutics Corp (NYSE:CHRO)
Health Care/Life Sciences • Pharmaceuticals
CIK 1919246
Company
Chromocell Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. The company was founded on March 19, 2021 and is headquartered in Freehold, NJ.
Address
4400 Route 9 South
Suite 1000
07728, New Jersey 08906
4400 Route 9 South
Suite 1000
07728, New Jersey 08906
Employees
6
6
Key Executives
Board Of Directors
Vice Chairman & Chief Strategy Officer Christian Kopfli LLD |
Director Ezra M Friedberg |
Chairman Todd C Davis MBA |
SEC filings
Date | Form | Event |
---|---|---|
19 Dec, 2024 | EFFECT | |
11 Dec, 2024 | POS AM | |
2 Dec, 2024 | EFFECT | |
22 Nov, 2024 | POS AM | |
22 Nov, 2024 | POS AM | |
21 Nov, 2024 | 8-K | |
19 Nov, 2024 | 8-K12G3 | |
18 Nov, 2024 | 8-K | |
15 Nov, 2024 | 4 | |
15 Nov, 2024 | 4 | |
15 Nov, 2024 | 4 | |
13 Nov, 2024 | 424B3 | |
13 Nov, 2024 | 10-Q | |
13 Nov, 2024 | SC 13G/A | |
13 Nov, 2024 | 424B3 | |
24 Oct, 2024 | 8-K | |
26 Sep, 2024 | DEF 14A | |
16 Sep, 2024 | 4 | |
16 Sep, 2024 | 4 | |
12 Sep, 2024 | 4 | |
9 Sep, 2024 | PRE 14A | |
13 Aug, 2024 | 424B3 | |
13 Aug, 2024 | 10-Q | |
13 Aug, 2024 | 424B3 | |
7 Aug, 2024 | 8-K | |
6 Aug, 2024 | 424B3 | |
6 Aug, 2024 | D | |
6 Aug, 2024 | EFFECT | |
6 Aug, 2024 | D | |
2 Aug, 2024 | UPLOAD | |
2 Aug, 2024 | CORRESP | |
29 Jul, 2024 | 424B3 | |
29 Jul, 2024 | S-1 | |
29 Jul, 2024 | 424B3 | |
29 Jul, 2024 | 8-K | |
2 Jul, 2024 | 3/A | |
2 Jul, 2024 | 4 | |
18 Jun, 2024 | 4 | |
18 Jun, 2024 | 4 | |
18 Jun, 2024 | 4 | |
18 Jun, 2024 | 4 | |
18 Jun, 2024 | 4/A | |
18 Jun, 2024 | 4 | |
18 Jun, 2024 | 4 | |
15 May, 2024 | 424B3 | |
15 May, 2024 | 424B3 | |
15 May, 2024 | 10-Q | |
17 Apr, 2024 | 424B3 | |
17 Apr, 2024 | 424B3 | |
17 Apr, 2024 | POS EX | |
16 Apr, 2024 | 10-K | |
15 Apr, 2024 | S-8 | |
9 Apr, 2024 | 8-K | |
1 Apr, 2024 | NT 10-K | |
21 Mar, 2024 | 8-K | |
18 Mar, 2024 | 8-K | CEO Change |
13 Mar, 2024 | 8-K | |
12 Mar, 2024 | 4/A | |
4 Mar, 2024 | SC 13G | |
1 Mar, 2024 | SC 13G | |
1 Mar, 2024 | SC 13G | |
1 Mar, 2024 | SC 13G | |
1 Mar, 2024 | SC 13G | |
1 Mar, 2024 | SC 13G | |
26 Feb, 2024 | SC 13D | |
23 Feb, 2024 | 4 | |
23 Feb, 2024 | 4 | |
23 Feb, 2024 | 4 | |
22 Feb, 2024 | 8-K | |
20 Feb, 2024 | 424B4 | IPO completed |
20 Feb, 2024 | 424B4 | |
20 Feb, 2024 | SEC STAFF | |
16 Feb, 2024 | POS EX | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | CERT | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 3 | |
15 Feb, 2024 | 8-A12B | |
15 Feb, 2024 | 3 | |
14 Feb, 2024 | S-1/A | |
14 Feb, 2024 | EFFECT | |
12 Feb, 2024 | CORRESP | |
12 Feb, 2024 | CORRESP | |
12 Feb, 2024 | FWP | |
12 Feb, 2024 | S-1/A | |
7 Feb, 2024 | FWP | |
7 Feb, 2024 | S-1/A | |
31 Jan, 2024 | FWP | |
30 Jan, 2024 | CORRESP | |
30 Jan, 2024 | S-1/A | |
25 Jan, 2024 | UPLOAD | |
23 Jan, 2024 | SEC STAFF | |
16 Jan, 2024 | S-1/A | |
8 Nov, 2023 | FWP | |
8 Nov, 2023 | S-1/A | |
25 Oct, 2023 | S-1/A | |
24 Oct, 2023 | UPLOAD | |
16 Oct, 2023 | FWP | |
16 Oct, 2023 | S-1/A | |
13 Oct, 2023 | CORRESP | |
12 Sep, 2023 | UPLOAD | |
1 Sep, 2023 | CORRESP | |
1 Sep, 2023 | S-1/A | |
24 Jul, 2023 | CORRESP | |
20 Jul, 2023 | S-1/A | |
10 Jul, 2023 | UPLOAD | |
30 Jun, 2023 | S-1/A | |
30 Jun, 2023 | CORRESP | |
19 May, 2023 | UPLOAD | |
1 May, 2023 | CORRESP | |
1 May, 2023 | S-1/A | |
23 Jan, 2023 | UPLOAD | |
20 Jan, 2023 | S-1/A | |
11 Jan, 2023 | S-1 | |
11 Jan, 2023 | CORRESP | |
31 Oct, 2022 | UPLOAD | |
17 Oct, 2022 | DRS/A | |
14 Oct, 2022 | DRSLTR | |
3 Oct, 2022 | UPLOAD | |
6 Sep, 2022 | DRS |
Last update:2024-03-12 12:02:07.407338
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.